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Enigmatic Ladies of the Rings: How
Cohesin Dysfunction Affects Myeloid
Neoplasms Insurgence
Alex Pezzotta, Mara Mazzola, Marco Spreafico, Anna Marozzi* and Anna Pistocchi*
Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan, Italy
The genes of the cohesin complex exert different functions, ranging from the
adhesion of sister chromatids during the cell cycle, DNA repair, gene expression and
chromatin architecture remodeling. In recent years, the improvement of DNA sequencing
technologies allows the identification of cohesin mutations in different tumors such
as acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL), and
myelodysplastic syndromes (MDS). However, the role of cohesin dysfunction in cancer
insurgence remains elusive. In this regard, cells harboring cohesin mutations do not
show any increase in aneuploidy that might explain their oncogenic activity, nor cohesin
mutations are sufficient to induce myeloid neoplasms as they have to co-occur with
other causative mutations such as NPM1, FLT3-ITD, and DNMT3A. Several works,
also using animal models for cohesin haploinsufficiency, correlate cohesin activity with
dysregulated expression of genes involved in myeloid development and differentiation.
These evidences support the involvement of cohesin mutations in myeloid neoplasms.
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COHESIN STRUCTURE AND FUNCTIONS
One of the biological meaning of a living organism is the possibility to divide by replicating
DNA and generate a new organism. To accomplish this, the genome duplication should be
error free and the daughter cell should properly inherit the genetic material from the mother
cell. The cohesin proteins are required during this multistep process: in interphase to maintain
genome stability during DNA double strand break repair (Watrin and Peters, 2009; Losada,
2014), in S-phase to enforce Sister Chromatid Cohesion (SCC) throughout DNA replication
(Peters et al., 2008), and in M-phase to ensure proper chromosome distribution into dividing
cells (Jeppsson et al., 2014). Since the cohesin protein complex has essential roles in the cell,
members of the cohesin complex are found from bacteria to humans and are evolutionary
and functionally conserved. The ability of cohesin to perform these functions resides in their
property to encircle the DNA, creating topological links between chromatin fibers. To mediate
sister chromatids tethering and segregation or DNA double strand break repair, the cohesin
complex binds to the DNA in a trans conformation. However, cohesin might also encircle the
DNA in cis, forming chromatin loops and contributing to gene regulation by modulating genome
architecture or joining two distant segments of the genome. In vertebrates, the ring that embraces
the DNA is formed by coiled-coil heterodimers of Structural Maintenance of Chromosomes (SMC)
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subunits SMC1 and SMC3, by the alpha-kleisin subunit RAD21
that brings in connection the ATPase head domains of SMC
proteins and stabilizes their interactions (Nasmyth, 2011), and
by the stromal antigens STAG1/STAG2 (SA1/SA2) (Canudas
and Smith, 2009; Remeseiro et al., 2012). Although cohesin
proteins are intrinsically able to topologically bind to the DNA
(Gligoris et al., 2014), the loading of the complex is not
efficient in the absence of the NIPBL/MAU2 heterodimer. As
stated by their name, cohesin becomes “cohesive” only when
the SMC3 head domain subunits are acetylated by the acetyl-
transferase ESCO1/ESCO2. The release of the complex from the
DNA is achieved by the separase-mediated proteolytic cleavage
of RAD21 (Uhlmann et al., 2000), the HDAC8-mediated de-
acetylation of SMC3, or the opening of the RAD21-SMC3
complex controlled by accessory proteins such as CDCA5
(soronin), PDS5 and WAPL (Ben-Shahar et al., 2008; Rowland
et al., 2009; Nishiyama et al., 2010; Tedeschi et al., 2013; Beckouët
et al., 2016; Figure 1A).
Recently, several studies were carried out to elucidate the
role of the cohesin ring in topological entrapment of DNA.
Biochemical and crystallographic studies in yeast led to the
identification of an interlocking gate for the transportation of
DNA across the cohesin ring (Murayama and Uhlmann, 2015),
and of a specific HEAT-domain required for the binding of the
DNA to the SMC3-RAD21 complex due to a positively charged
surface (Li et al., 2018). Other studies using Chromosome
Conformation Capture-derived approaches such as 5C and Hi-C,
allowed the identification of a role for cohesin in the formation
and stabilization of Topologically Associating Domains (TADs),
genomic regions spanning form 200 kb to 1 Mb in mammals,
that are thought to contribute to gene expression by remodeling
chromosome architecture (Dixon et al., 2016). In a recent
work using the smallest human chromosome 21, Bernardi
demonstrated that the formation of TADs is related to the
3D structures of the corresponding GC-rich isochores. These
“primary TADs” are bound to the cohesin complex that actively
slides down, generating an extrusion loop (Bernardi, 2018). In
another work it has been hypothesized that the movement of
the cohesin complex along the extrusion loop is mediated by
the pushing of the RNA polymerase (Björkegren and Baranello,
2018). Indeed, in Drosophila and mammals, cohesin can activate
or silence genes by interacting with RNA polymerase II (RNA Pol
II) (Misulovin et al., 2008; Schaaf et al., 2009; Fay et al., 2011). For
example, by comparing NIPBL and RNA Pol II binding sites, it
has been shown that NIPBL binds 100–200 nucleotides upstream
of RNA Pol II (Zuin et al., 2014). The extrusion loop made
by cohesin stops when DNA is occupied by the CCTC-binding
factor (CTCF). In human and mammals, cohesin and CTCF co-
localize at several loci contributing to topological organization of
the genome: when CTCF is depleted, the cohesin complex is not
found at CTCF sites (Wendt et al., 2008) but is still able to bind
to other chromatin regions (Figure 1B).
Hence, cohesin proteins regulate both positively or negatively
chromatin architecture and gene expression, by recognizing
specific sites on the genome alone or in combination with
different proteins, and modifying the interaction between
enhancers and promoters.
COHESIN AND TUMOURIGENESIS
Several evidences suggest that altered gene expression due to
cohesin dysfunction could affect tumourigenesis. Indeed, cohesin
or its regulators are frequently mutated in different types of
tumors such as colorectal cancer (NIPBL) (Barber et al., 2008),
glioblastoma, Ewing’s sarcoma, urothelial bladder carcinoma,
melanoma (STAG2) (Solomon et al., 2011, 2013; Balbás-Martínez
et al., 2013) and myeloid neoplasms (STAG1, STAG2, SMC3,
and RAD21) (Dolnik et al., 2012; Kon et al., 2013). In addition,
mutations in genomic binding sites of CTCF/cohesin (Katainen
et al., 2015) or changes in cohesin protein levels (RAD21) have
been associated to cancers (Yan et al., 2012). Since the cohesin
complex is involved in chromosome segregation and DNA repair,
it is not surprising that cohesin mutations or dysfunctions
could enhance tumorigenesis. However, the association between
cohesin mutations and genome instability in cancer is still
controversial and not always reported (Balbás-Martínez et al.,
2013; Taylor et al., 2014; Thol et al., 2014). To note, patients
affected by the Cornelia de Lange Syndrome (CdLS) caused
by germline mutations in cohesin genes (∼65% NIPBL, ∼5%
SMC1A and HDAC8, 1–2% SMC3 and RAD21) (Mannini et al.,
2013; Singh and Gerton, 2015), rarely develop cancers and likely
not for genomic instability but as a consequence of their clinical
features (e.g., gastric reflux) (Schrier et al., 2011; Deardorff et al.,
2012). Since CdLS and tumors share same types of mutations
in cohesin genes (for NIPBL heterozygous mutations, mainly
non-sense, leading to haploinsufficiency; for SMC1A hemizygous
mutations, mainly missense, probably leading to a dominant
negative effect) (Mannini et al., 2013; Singh and Gerton, 2015), it
has been hypothesized that they differ in their physiopathological
contest. Indeed, in tumors somatic cohesin mutations occur in
adult and terminally differentiated cells while in CdLS germline
cohesin mutations occur in a developing and embryonic tissue.
In addition, conversely to CdLS in which cohesin mutations
are causative, in cancer cohesin mutations do not initiate but
contribute to tumorigenesis when they co-occur with additional
mutations. A study concerning AML identified 37 patients with
mutation in one of the cohesin genes and, among them, the
81.1% had an additional mutation in genes causative for AML
insurgence such as FLT3-ITD (21.6%), NPM1 (21.6%), RUNX1 or
ASXL1 (Tsai et al., 2017).
COHESIN MUTATIONS IN MYELOID
NEOPLASMS
Acute myeloid leukemia (AML) is a heterogeneous group of
hematologic aggressive neoplasms of bone marrow, characterized
by irreversible expansion of precursor myeloid blasts defective in
their differentiation and function (Löwenberg et al., 1999; Ley
et al., 2008; Naoe and Kiyoi, 2013). The leukemic mutations
are serially acquired in clones of long-lived self-renewing
hematopoietic stem cells (HSCs), termed pre-leukemic HSCs (Jan
and Majeti, 2013; Corces-Zimmerman and Majeti, 2014).
Among the novel recurrently mutated genes in AML patients,
there are the members of the cohesin complex which occur
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FIGURE 1 | The cohesin complex and accessory proteins: structure (A) and topological interactions with the DNA (B).
in approximately 15% of AML cases (Thota et al., 2014).
Interestingly, no correlation between mutated cohesin genes and
prognosis was observed, and most of clinical features of AML
patients with or without mutations in cohesin were similar (Thol
et al., 2014). Thol and colleagues characterized the genomes
of 389 uniformly treated AML patients in order to dissect the
clinical and prognostic implications of mutated cohesin. A total
of 23 patients (5.9%) had mutations in the cohesin genes and
the most frequently mutated were STAG1 (1.8%), STAG2 (1.3%),
and SMC3 (1.3%), while mutations in RAD21 and SMC1A were
rarer events. Previously, The Cancer Genome Atlas identified
mutations in cohesin in 26 out of 200 (13%) primary AML adult
patients, with a higher mutations frequency in STAG2, SMC1A,
SMC3, RAD21 meanwhile no mutation in STAG1 were observed
in comparison to Thol and colleagues’ analysis (Ley et al., 2013;
Thol et al., 2014). This discrepancy could be due to different
approaches used to validate mutations (Thol et al., 2014).
In myelodysplastic syndromes (MDS), a heterogeneous group
of clonal hematopoietic disorders characterized by cytopenia,
ineffective hematopoiesis and an increased risk of progression to
AML (Haferlach et al., 2014; Shallis et al., 2018), RAD21, STAG2,
and SMC1A are the most frequently mutated genes (∼15%) and
are associated with poor survival (Cazzola et al., 2013; Kon et al.,
2013; Haferlach et al., 2014; Malcovati et al., 2014; Thota et al.,
2014). The identified cohesin mutations in AML patients are
typically classified in two categories: mutations in RAD21 and
STAG2 are mainly truncation or frame-shift while mutations
in SMC3 and SMC1A are mainly missense (Kon et al., 2013;
Thota et al., 2014). Genomic deletions have also been found for
RAD21 and STAG2 (Rocquain et al., 2010). Importantly, cohesin
mutations are mutually exclusive suggesting that a single altered
component is sufficient to affect the tumor suppressive function
of the whole cohesin complex in myeloid leukemogenesis (Welch
et al., 2012; Solomon et al., 2014).
The frequency of cohesin mutations is surprisingly higher
in acute megakaryoblastic leukemia (AMKL), a rare sub-type
of AML (AML-M7) characterized by defective megakaryocytes
proliferation and differentiation (Ley et al., 2013; Yoshida
et al., 2013). AMKL represents 4–15% of pediatric AML
and is predominantly found in Down Syndrome children
(DS) together with somatic GATA1 mutations (Gruber and
Downing, 2015). GATA1 mutated isoforms cause the hyper-
proliferation of megakaryocyte progenitors during early fetal
liver hematopoiesis and lead to transient abnormal myelopoiesis
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FIGURE 2 | In-vitro (A) and in-vivo (B,C) models for the study of cohesin roles in hematopoiesis.
(TAM) (Hitzler et al., 2003; Rainis et al., 2003). Up to 10% of
TAM cases typically resolve spontaneously while 30% of them
develop in AMKL during childhood with the accumulation
of somatic mutations in different genomic regions (Rainis
et al., 2003; Yoshida et al., 2013). Sequencing analysis revealed
mutations and deletions in STAG2, RAD21, SMC3, SMC1A, and
NIPBL in almost 53% of DS-AMKL patients but none in the
TAM clones, indicating that cohesin mutations are involved
in neoplastic transformation from TAM to AMKL. Only few
non-DS-AMKL patients had cohesin mutations, suggesting that
mutated cohesin is a DS-AMKL feature. Different works tried
to dissect the effects of cohesin haploinsufficiency and altered
GATA1 binding to the chromatin (Yoshida et al., 2013; Fisher
et al., 2017). GATA1 mutations were strictly linked to the
context of trisomy 21 in DS patients (Shimizu et al., 2008) and
this condition provided the cellular setting for the persistence
and eventual transformation of GATA1 mutant cells. Moreover,
GATA1 mutations involve a region that mediates GATA1-
RUNX1 interaction during normal megakaryopoiesis (Elagib
et al., 2003). Interestingly, the dosage effect caused by trisomy
21 hyper-activated the Wnt signaling in DS-AMKL patients.
This is accomplished by the downregulation of the tumor
suppressor gene APC and stabilization of the active form of
beta-catenin via miR-99a/100-125 (Emmrich et al., 2014). The
interaction between cohesin and Wnt/beta-catenin signaling has
been described in different models of cancer (Ghiselli et al.,
2003), and in our zebrafish model with cohesin haploinsufficiency
(Pistocchi et al., 2013; Fazio et al., 2016; Mazzola et al., 2019),
suggesting a possible effect of cohesin mutations and Wnt/beta-
catenin signaling dysregulation in DS-AMKL.
COHESIN, GENE REGULATION AND
ANIMAL MODELS
Cohesin mutations are associated to myeloid neoplasms,
but are not causative of tumor onset indicating that other
pathways might be relevant. Since cohesin mutations are
often described as early, founder mutations in pre-leukemic
HSCs (Corces-Zimmerman and Majeti, 2014), several groups
investigated the role of cohesin complex in differentiation
and self-renewal of HSCs and of their progenitor cells
(HSPCs), and leukemogenic transformation using in-vitro and
in-vivo models (Figures 2A–C).
Mullenders and colleagues described the role of cohesin
in HSCs homeostasis (Mullenders et al., 2015). Firstly, they
transduced murine bone marrow c-Kit+ HSPCs with shRNA
against Rad21, Smc3, and Smc1a demonstrating a rapid increase
of their replating capacity and defects in myeloid differentiation.
Then, they generated a mouse model with cohesin down-
regulation showing clinically features of myeloid neoplasia
but not genomic alteration due to cohesin dysregulation.
Moreover, they demonstrated that HSCs and myeloid precursors
were subjected to changes in gene regulation and chromatin
accessibility as a consequence of cohesin down-regulation
(Mullenders et al., 2015). The correlation between the increase
of hematopoietic progenitors and cohesin downregulation has
been also described in a mouse model generated by Viny
and colleagues. Cells derived from this mouse with combined
effects of Smc3 haploinsufficiency and FLT3-ITD mutation,
showed increased HSPCs proliferation and survival rates and
a simultaneous decrease in myeloid progenitors (Viny et al.,
2015). The role of the cohesin complex as a major regulator
of HSCs has also been described by Galeev and colleagues
with genome wide RNAi analyses on primary human cord
blood derived CD34+ cells with cohesin knock-down (Galeev
et al., 2016). They demonstrated that in sorted CD34+ cells,
the transfection of shRNA against RAD21, STAG1-2 and SMC3
negatively affected differentiation and enhanced HSCs expansion
in vitro and in vivo when these cells were transplanted in
immunodeficient mice (Figure 2B). Transcriptome analyses
on cohesin-deficient CD34+ cells demonstrated an increased
expression of genes responsible for the stem cell phenotype.
Mazumdar and colleagues identified genomic regions with
altered chromatin accessibility following RAD21 or SMC1A
mutations in primary human HSPCs. Using the transposase-
accessible chromatin and sequencing (ATAC-seq) technique,
they found increased accessibility of GATA2, RUNX1 and ERG
DNA binding motifs when RAD21 and SMC1A were mutated
in comparison to controls. They also demonstrated that the
block in the HSPCs differentiation was specifically due to
the increased activity of these transcription factors as their
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shRNA-mediated silencing rescued the differentiation defects
of cohesin-mutated-HSPCs (Mazumdar and Majeti, 2017)
(Figure 2A). In a murine model, the loss of the Asxl1 gene
that is frequently mutated in different myeloid malignancies
with poor prognosis, reduced the genome binding of RAD21
and SMC1A and altered the expression of their target genes
in cells enriched for myeloid progenitors Lin-cKit+ (LK)
(Li et al., 2017).
RUNX1, an essential regulator of hematopoiesis frequently
involved in leukemia insurgence, is also related to cohesin,
as demonstrated by Horsfield and colleagues using a zebrafish
model. The zebrafish rad21nz171 mutant completely lacked
early runx1 expression in hematopoietic compartments, while
monoallelic loss of rad21 reduced the transcription of runx1,
suggesting a dose-dependent modulation controlled by Rad21.
Early hematopoiesis in rad21nz171 mutant was not dramatically
affected except for the gata1 downregulated expression, while
later differentiation was severely reduced, indicating that the
altered expression of markers of late hematopoiesis depends
on the loss of runx1 and reduction of gata1 (Horsfield et al.,
2007; Figure 2C).
The hypothesis that cohesin dysfunction in HSPCs might alter
the expression of hematopoietic genes was further investigated
going inside the mechanism through which cohesin accomplish
this. Fisher and colleagues demonstrated that cohesin complex
binds to and regulates the Polycomb Repressive Complex
2 (PRC2) to silence Hoxa7 and Hoxa9 genes involved in
HSPCs proliferation. Mutations in cohesin (RAD21) enhanced
HSPCs proliferation but the phenotype could be rescued when
Hoxa7 or Hoxa9 genes were simultaneously knocked-down
(Fisher et al., 2017). The authors argued that the cohesin-
mediated regulation of PRC2 interaction with Hoxa locus was
accomplished through remodeling of chromatin architecture.
Indeed, cohesin proteins interact with CTCF in DNA binding,
specifically in the establishment of TADs (Merkenschlager and
Nora, 2016; Bernardi, 2018). The binding of CTCF, together
with the epigenetic chromatin-remodeling factor Smarca5 and
cohesin was also found at upstream regulatory element (URE)
of SPI1 gene, a master transcription factor of myeloid cell
differentiation. This recruitment was disrupted in AML blasts
suggesting its involvement in tumor insurgence (Dluhosova
et al., 2014). The specific action of the cohesin complex on
myeloid cells was also observed in one case of gene fusion.
Murine hematopoietic cells transfected with the fusion gene
NIPBL-HOXB9 exhibited increased in vitro colony replating
capacity with hallmarks of myeloid progenitors (Dang et al.,
2017). In our recent work, we used zebrafish to confirm
that other mutations might dysregulate cohesin expression. In
this regard, we observed that AML patients carrying NPM1
mutations showed a specific NIPBL downregulation and a
zebrafish model with NIPBL haploinsufficiency presented defects
in myeloid cell differentiation, demonstrating that animal models
could enhance the comprehension of the action of multiple
mutations/dysregulations (Mazzola et al., 2019).
CONCLUSION AND FUTURE
PERSPECTIVES
In myeloid neoplasms cohesin mutations occur with low
frequency in comparison to other more frequently mutated
genes and are not sufficient, alone, to drive to tumourigenesis.
However, cohesin mutations occur early in the clonal hierarchy
and cohesin dysfunction enhances HSC and HSPCs proliferation
and controls the expression of genes involved in myeloid
differentiation. Therefore, cohesin might be considered as
promising pharmacological target for myeloid malignancies.
Some drugs already used in AML clinical trials such as Dot1I
methyltransferase inhibitors (Bernt et al., 2011) or azacitidine,
have been proved to be efficient in the rescue of the phenotype
caused by cohesin mutations (Fisher et al., 2017; Tothova et al.,
2017). Thus, the dissection of molecular pathways altered by
cohesin dysfunction might allow the discovery of new therapeutic
targets downstream of cohesin. In this regard, the screening
for cohesin mutations of larger cohorts of patients or the
development of animal models with cohesin haploinsufficiency
are required to address this intriguing possibility. Moreover,
the co-occurrence of mutations in cohesin and causative genes
of myeloid neoplasms (e.g., FLT3-ITD, DNMT3A, NPM1, and
TET2), leads to the hypothesis that the efforts to develop therapies
for AML might be improved by combining those targeting
specific genes and those directed on shared targets, as well as by
combining multiple therapies to treat diverse sub-clones.
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